TRELEGY ELLIPTA

Fluticasone furoate
Umeclidinium bromide
Vilanterol trifenatate

1. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 92 micrograms fluticasone furoate, 65 micrograms umeclidinium bromide equivalent to 55 micrograms umeclidinium and 22 micrograms vilanterol (as trifenatate). This corresponds to a pre-dispensed dose of 100 micrograms fluticasone furoate, 74.2 micrograms umeclidinium bromide equivalent to 62.5 micrograms umeclidinium and 25 micrograms vilanterol (as trifenatate).

Excipient with known effect
Each delivered dose contains approximately 25 mg of lactose monohydrate.

For the full list of excipients, *see section 5.1*.

2. PHARMACEUTICAL FORM

Inhalation powder, pre-dispensed (inhalation powder).

White powder in a light grey inhaler (*ELLIPTA*) with a beige mouthpiece cover and a dose counter.

3. CLINICAL PARTICULARS

3.1 Therapeutic indications

ASTHMA

TRELEGY ELLIPTA is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled with a combination of inhaled corticosteroid and a long-acting beta$_2$-agonist. *TRELEGY ELLIPTA* is not indicated for relief of acute bronchospasm.

COPD

TRELEGY ELLIPTA is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta$_2$-agonist or a combination of a long-acting beta$_2$-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations *see section 4.1*).

3.2 Posology and method of administration

Posology
TRELEGY ELLIPTA is for oral inhalation only. *TRELEGY ELLIPTA* should be administered once daily, either morning or evening, but at the same time each day.

If a dose is missed the next dose should be inhaled at the usual time the next day.

Populations
ASTHMA
Patients should be made aware that *TRELEGY ELLIPTA* must be used regularly, even when asymptomatic.

If symptoms arise in the period between doses, an inhaled, short-acting beta$_2$-agonist should be taken for immediate relief.

Patients should be regularly reassessed by a healthcare professional so that the strength of *TRELEGY ELLIPTA* they are receiving remains optimal and is only changed on medical advice.

Adults
The recommended dose of *TRELEGY ELLIPTA* is:

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

One inhalation of *TRELEGY ELLIPTA* 100/62.5/25 micrograms once daily or one inhalation of *TRELEGY ELLIPTA* 200/62.5/25 micrograms once daily.

A starting dose of *TRELEGY ELLIPTA* 100/62.5/25 micrograms should be considered for patients who require a low to mid dose of inhaled corticosteroid in combination with a long-acting muscarinic receptor antagonist and a long acting beta$_2$-agonist.

TRELEGY ELLIPTA 200/62.5/25 micrograms should be considered for patients who require a higher dose of inhaled corticosteroid in combination with a long-acting muscarinic receptor antagonist and a long acting beta$_2$-agonist.

If patients are inadequately controlled on *TRELEGY ELLIPTA* 100/62.5/25 micrograms, consider increasing the dose to 200/62.5/25 micrograms, which may provide additional improvement in asthma control.

Children and adolescents
The safety and efficacy of *TRELEGY ELLIPTA* have not been established in children or adolescents less than 18 years of age.

COPD
Adults
The recommended and maximum dose is one inhalation of *TRELEGY ELLIPTA* 100/62.5/25 micrograms once daily.

Children and adolescents
Use in patients less than 18 years of age is not relevant to the COPD indication for this product.

ASTHMA and COPD
Elderly patients
No dosage adjustment is required in patients over 65 years (*see section 4.2*).

Renal impairment
No dosage adjustment is required for patients with renal impairment (*see section 4.2*).

Hepatic impairment
No dose adjustment is required in patients with mild, moderate or severe hepatic impairment. *TRELEGY ELLIPTA* should be used with caution in patients with moderate to severe hepatic impairment (*see sections 3.4 and 4.2*).

Method of administration
TRELEGY ELLIPTA is for inhalation use only.

Instructions for use:
The following instructions for the 30 dose (30 day supply) *ELLIPTA* inhaler also apply to the 14 dose (14 day supply) *ELLIPTA* inhaler.

a) Prepare a dose
Open the cover when ready to inhale a dose. The inhaler should not be shaken.

Slide the cover down fully until a “click” is heard. The medicinal product is now ready to be inhaled.

The dose counter counts down by 1 to confirm. If the dose counter does not count down as the “click” is heard, the inhaler will not deliver a dose and should be taken back to a pharmacist for advice.

b) How to inhale the medicinal product

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

The inhaler should be held away from the mouth breathing out as far as is comfortable, but not breathing out into the inhaler.

The mouthpiece should be placed between the lips and the lips should then be closed firmly around it. The air vents should not be blocked with fingers during use.

- Inhale with one long, steady, deep breath in. This breath should be held in for as long as possible (at least 3-4 seconds).
- Remove the inhaler from the mouth.
- Breathe out slowly and gently.

The medicinal product may not be tasted or felt, even when using the inhaler correctly.

The mouthpiece of the inhaler may be cleaned using a dry tissue before closing the cover.

c) Close the inhaler and rinse your mouth
Slide the cover upwards as far as it will go, to cover the mouthpiece.

Rinse your mouth with water after you have used the inhaler, do not swallow.

This will make it less likely to develop a sore mouth or throat as side effects.

For further instructions on handling the device, *see section 5.6*.

3.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in *section 5.1*.

3.4 Special warnings and precautions for use
Not for acute use
There are no clinical data to support the use of *TRELEGY ELLIPTA* for the treatment of acute episodes of bronchospasm, or to treat an acute COPD exacerbation (i.e. as a rescue therapy).

Deterioration of disease
Increasing use of short-acting bronchodilators to relieve symptoms may indicate deterioration of disease control. In the event of deterioration of COPD during treatment with *TRELEGY ELLIPTA*, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken.

Patients should not stop therapy with *TRELEGY ELLIPTA* without physician supervision since symptoms may recur after discontinuation.

Paradoxical bronchospasm
Administration of fluticasone furoate/umeclidinium/vilanterol may produce paradoxical bronchospasm with an immediate wheezing and shortness of breath after dosing and may be life-threatening. Treatment with *TRELEGY ELLIPTA* should be discontinued immediately if paradoxical bronchospasm occurs. The patient should be assessed and alternative therapy instituted if necessary.

Cardiovascular effects
Cardiovascular effects, such as cardiac arrhythmias, e.g. atrial fibrillation and tachycardia, may be seen after the administration of muscarinic receptor antagonists and sympathomimetics, including umeclidinium and vilanterol, respectively. Therefore, *TRELEGY ELLIPTA* should be used with caution in patients with unstable or life-threatening cardiovascular disease.

Patients with hepatic impairment
Patients with moderate to severe hepatic impairment receiving *TRELEGY ELLIPTA* should be monitored for systemic corticosteroid-related adverse reactions (*see section 4.2*).

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

Systemic corticosteroid effects

Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur than with oral corticosteroids.

Visual disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Coexisting conditions

TRELEGY ELLIPTA should be used with caution in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta$_2$-adrenergic agonists.

TRELEGY ELLIPTA should be administered with caution in patients with pulmonary tuberculosis or in patients with chronic or untreated infections.

Anticholinergic activity

TRELEGY ELLIPTA should be used with caution in patients with narrow-angle glaucoma or urinary retention. Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using *TRELEGY ELLIPTA* and to contact their doctor immediately should any of these signs or symptoms develop.

Pneumonia in patients with COPD

An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.

There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products.

Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.

Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.

Hypokalaemia

Beta$_2$-adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation.

No clinically relevant effects of hypokalaemia were observed in clinical studies with *TRELEGY ELLIPTA* at the recommended therapeutic dose. Caution should be exercised when *TRELEGY ELLIPTA* is used with other medicinal products that also have the potential to cause hypokalaemia (*see section 3.5*).

Hyperglycaemia

Beta$_2$-adrenergic agonists may produce transient hyperglycaemia in some patients. No clinically relevant effects on plasma glucose were observed in clinical studies with fluticasone furoate/umeclidinium/vilanterol at the recommended therapeutic dose. There have been reports of increases in blood glucose levels in diabetic patients treated with fluticasone

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

furoate/umeclidinium/vilanterol and this should be considered when prescribing to patients with a history of diabetes mellitus. Upon initiation of treatment with *TRELEGY ELLIPTA*, plasma glucose should be monitored more closely in diabetic patients.

Excipients

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not use this medicinal product.

3.5 Interaction with other medicinal products and other forms of interaction

Clinically significant drug interactions mediated by fluticasone furoate/umeclidinium/vilanterol at clinical doses are considered unlikely due to the low plasma concentrations achieved after inhaled dosing.

Interaction with beta-blockers

Beta$_2$-adrenergic blockers may weaken or antagonise the effect of beta$_2$-adrenergic agonists, such as vilanterol. If beta-blockers are required, cardioselective beta-blockers should be considered, however, caution should be exercised during concurrent use of both non-selective and selective beta-blockers.

Interaction with CYP3A4 inhibitor

Fluticasone furoate and vilanterol are rapidly cleared by extensive first pass metabolism mediated by enzyme CYP3A4.

Caution is advised when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, cobicistat-containing products) as there is potential for increased systemic exposure to both fluticasone furoate and vilanterol, which could lead to an increased potential for adverse reactions. Co administration should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid adverse reactions, in which case patients should be monitored for systemic corticosteroid adverse reactions. A repeat dose study was performed in healthy subjects with the fluticasone furoate/vilanterol combination (184/22 micrograms) and ketoconazole (400 milligrams, a strong CYP3A4 inhibitor). Co-administration increased mean fluticasone furoate $AUC_{(0-24)}$ and C_{max} by 36% and 33%, respectively. The increase in fluticasone furoate exposure was associated with a 27% reduction in 0-24 hours weighted mean serum cortisol. Co-administration increased mean vilanterol $AUC_{(0-t)}$ and C_{max} by 65% and 22%, respectively. The increase in vilanterol exposure was not associated with an increase in beta$_2$-agonist related systemic effects on heart rate or blood potassium.

Interaction with CYP2D6 inhibitors/CYP2D6 polymorphism

Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6). The steady-state pharmacokinetics of umeclidinium was assessed in healthy volunteers lacking CYP2D6 (poor metabolisers). No effect on umeclidinium AUC or C_{max} was observed at a dose 8-fold higher than the therapeutic dose. An approximately 1.3-fold increase in umeclidinium AUC was observed at 16-fold higher dose with no effect on umeclidinium C_{max}. Based on the magnitude of these changes, no clinically relevant drug interaction is expected when fluticasone furoate/umeclidinium/vilanterol is co-administered with CYP2D6 inhibitors or when administered to patients who are genetically deficient in CYP2D6 activity (poor metabolisers).

Interaction with P-glycoprotein inhibitors

Fluticasone furoate, umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The effect of the moderate P-gp inhibitor verapamil (240 mg once daily) on the steady-state pharmacokinetics of umeclidinium and vilanterol was assessed in healthy volunteers. No effect of verapamil was observed on umeclidinium or vilanterol C_{max}. An approximately 1.4-fold increase in umeclidinium AUC was observed with no effect on vilanterol AUC. Based on the magnitude of these changes, no clinically relevant drug interaction is expected when fluticasone

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

furoate/umeclidinium/vilanterol is co-administered with P-gp inhibitors. Clinical pharmacology studies with a specific P-gp inhibitor and fluticasone furoate have not been conducted.

Other long acting antimuscarinics and long acting beta$_2$- adrenergic agonists
Co-administration of *TRELEGY ELLIPTA* with other long-acting muscarinic antagonists or long-acting beta$_2$-adrenergic agonists has not been studied and is not recommended as it may potentiate the adverse reactions (*see sections 3.8 and 3.9*).

Hypokalaemia
Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta$_2$-adrenergic agonists, therefore caution should be exercised (*see section 3.4*).

3.6 Fertility, pregnancy and lactation

Pregnancy
There are limited data from the use of fluticasone furoate/umeclidinium/vilanterol in pregnant women. Studies in animals have shown reproductive toxicity at exposures which are not clinically relevant (*see section 4.3*).

Administration of *TRELEGY ELLIPTA* to pregnant women should only be considered if the expected benefit to the mother justifies the potential risk to the foetus.

Breast-feeding
It is unknown whether fluticasone furoate, umeclidinium, vilanterol or their metabolites are excreted in human milk. However, other corticosteroids, muscarinic antagonists and beta$_2$-adrenergic agonists are detected in human milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue *TRELEGY ELLIPTA* therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility
There are no data on the effects of fluticasone furoate/umeclidinium/vilanterol on human fertility. Animal studies indicate no effects of fluticasone furoate, umeclidinium or vilanterol on male or female fertility (*see section 4.3*).

3.7 Effects on ability to drive and use machines

Fluticasone furoate/umeclidinium/vilanterol has no or negligible influence on the ability to drive and use machines.

3.8 Undesirable effects

Summary of the safety profile
The most frequently reported adverse reactions with *TRELEGY ELLIPTA* were nasopharyngitis (7%), headache (5%) and upper respiratory tract infection (2%).

Tabulated summary of adverse reactions
The safety profile of *TRELEGY ELLIPTA* is based on three phase III clinical studies and spontaneous reporting.

The first study included safety data from 911 patients with COPD who received fluticasone furoate/umeclidinium/vilanterol 92/55/22 micrograms, once daily, for up to 24 weeks, of whom 210 patients received fluticasone furoate/umeclidinium/vilanterol 92/55/22 micrograms once daily for up to 52 weeks, with an active comparator (study CTT116853, FULFIL).

The second study included safety data from 527 patients with COPD who received fluticasone furoate/umeclidinium/vilanterol (92/55/22 micrograms) and 528 patients with COPD who received

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

fluticasone furoate/vilanterol (92/22 micrograms) + umeclidinium (55 micrograms) once daily for up to 24 weeks (study 200812).

The third study included safety data from 4,151 patients with COPD who received fluticasone furoate/umeclidinium/vilanterol 92/55/22 micrograms once daily for up to 52 weeks, with two active comparators (study CTT116855, IMPACT).

Where adverse reaction frequencies differed between studies, the higher frequency is reported below.

Adverse reactions are listed by MedDRA system organ class.

The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data).

System Organ Class	Adverse reactions	Frequency
Infections and infestations	Pneumonia Upper respiratory tract infection Bronchitis Pharyngitis Rhinitis Sinusitis Influenza Nasopharyngitis Candidiasis of mouth and throat Urinary tract infection	Common
	Viral respiratory tract infection	Uncommon
Immune system disorders	Hypersensitivity reactions, including anaphylaxis, angioedema, urticaria, and rash	Rare
Nervous system disorders	Headache	Common
Eye disorders	Vision blurred (*see section 3.4*)	Not known
Cardiac disorders	Supraventricular tachyarrhythmia Tachycardia Atrial fibrillation	Uncommon
Respiratory, thoracic & mediastinal disorders	Cough Oropharyngeal pain	Common
	Dysphonia	Uncommon
Gastrointestinal disorders	Constipation	Common
	Dry mouth	Uncommon
Musculoskeletal and connective tissue disorders	Arthralgia Back pain	Common
	Fractures	Uncommon

Description of selected adverse reactions

Pneumonia

COPD

In a total of 1,810 patients with advanced COPD (mean post-bronchodilator screening FEV_1 45% of predicted, standard deviation (SD) 13%), 65% of whom had experienced a moderate/severe COPD exacerbation in the year prior to study entry (study CTT116853), there was a higher incidence of pneumonia events reported up to 24 weeks in patients receiving *TRELEGY ELLIPTA* (20 patients, 2%) than in patients receiving budesonide/formoterol (7 patients, <1%). Pneumonia which required hospitalisation occurred in 1% of patients receiving *TRELEGY ELLIPTA* and <1% of patients receiving budesonide/formoterol up to 24 weeks. One fatal case of pneumonia was reported in a patient who received *TRELEGY ELLIPTA*. In the subset of 430 patients treated for

up to 52 weeks, the incidence of pneumonia events reported in both *TRELEGY ELLIPTA* and budesonide/formoterol arms was equal at 2%. The incidence of pneumonia with *TRELEGY ELLIPTA* is comparable with that observed in the fluticasone furoate/vilanterol (FF/VI) 100/25 arm of FF/VI clinical studies in COPD.

In a 52-week study, with a total of 10,355 patients with COPD and a history of moderate or severe exacerbations within the prior 12 months (mean post-bronchodilator screening FEV_1 46% of predicted, SD 15%) (study CTT116855), the incidence of pneumonia was 8% (317 patients) for *TRELEGY ELLIPTA* (n=4,151), 7% (292 subjects) for fluticasone furoate/vilanterol (n=4,134), and 5% (97 subjects) for umeclidinium/vilanterol (n=2,070). Fatal pneumonia occurred in 12 of 4,151 patients (3.5 per 1,000 patient-years) receiving *TRELEGY ELLIPTA*, 5 of 4,134 patients (1.7 per 1,000 patient-years) receiving fluticasone furoate/vilanterol, and 5 of 2,070 patients (2.9 per 1,000 patient-years) receiving umeclidinium/vilanterol.

Asthma

In patients with asthma (study 205715) treated up to 52 weeks, the incidence of pneumonia was 1% (5 of 406 patients) for *TRELEGY ELLIPTA* 100/62.5/25 micrograms and <1% (4 of 408 patients) for *TRELEGY ELLIPTA* 200/62.5/25 micrograms. The incidence of pneumonia was 2% in the fluticasone furoate/vilanterol 100/25 micrograms (7 of 407 patients) and fluticasone furoate/vilanterol 200/25 micrograms (7 of 406 patients) groups.

The incidence of pneumonia events requiring hospitalisation was similar in the *TRELEGY ELLIPTA* and fluticasone furoate/vilanterol groups (<1% for all groups). There were no fatal pneumonia events.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via company reporting channel: email address yqq68540@gsk.com.

3.9 Overdose

An overdose will likely produce signs, symptoms or adverse effects associated with the individual components' pharmacological actions (e.g. Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, dry mouth, visual accommodation disturbances, tachycardia, arrhythmias, tremor, headache, palpitations, nausea, hyperglycaemia and hypokalaemia).

There is no specific treatment for an overdose with *TRELEGY ELLIPTA*. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

Cardioselective beta-blockade should only be considered for profound vilanterol overdose effects that are clinically concerning and unresponsive to supportive measures. Cardioselective beta-blocking medicinal products should be used with caution in patients with a history of bronchospasm.

Further management should be clinically indicated or as recommended by the national poisons centre, where available.

4. PHARMACOLOGICAL PROPERTIES

4.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics in combination with anticholinergics including triple combinations with corticosteroids, ATC code: R03AL08.

Mechanism of action

Fluticasone furoate/umeclidinium/vilanterol is a combination of inhaled synthetic corticosteroid, long-acting muscarinic receptor antagonist and long-acting beta$_2$-adrenergic agonist (ICS/LAMA/LABA). Following oral inhalation, umeclidinium and vilanterol act locally on airways to produce bronchodilation by separate mechanisms and fluticasone furoate reduces inflammation.

Fluticasone furoate
Fluticasone furoate is a corticosteroid with potent antiinflammatory activity. The precise mechanism through which fluticasone furoate affects asthma and COPD symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g. eosinophils, macrophages, lymphocytes) and mediators (e.g. cytokines and chemokines) involved in inflammation.

Umeclidinium
Umeclidinium is a long-acting muscarinic receptor antagonist (also referred to as an anticholinergic). Umeclidinium exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic receptors on airway smooth muscle. It demonstrates slow reversibility at the human M3 muscarinic receptor subtype *in vitro* and a long duration of action *in vivo* when administered directly to the lungs in pre-clinical models.

Vilanterol
Vilanterol is a selective long-acting, beta$_2$-adrenergic receptor agonist (LABA). The pharmacologic effects of beta$_2$-adrenergic agonists, including vilanterol, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3',5'- adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Pharmacodynamic effects
Cardiac electrophysiology
The effect of fluticasone furoate/umeclidinium/vilanterol on the QT interval has not been evaluated in a thorough QT (TQT) study. TQT studies for FF/VI and umeclidinium/vilanterol (UMEC/VI) did not show clinically relevant effects on QT interval at clinical doses of FF, UMEC and VI.

No clinically relevant effects on the QTc interval were observed on review of centrally read ECGs from 911 subjects with COPD exposed to fluticasone furoate/umeclidinium/vilanterol for up to 24 weeks, or in the subset of 210 subjects exposed for up to 52 weeks.

Clinical efficacy and safety
The efficacy of *TRELEGY ELLIPTA* (92/55/22 micrograms), administered as a once-daily treatment, has been evaluated in patients with a clinical diagnosis of COPD in two, active-controlled studies and in a single, non-inferiority study. All three studies were multicentre, randomised, double-blind studies that required patients to be symptomatic with a COPD Assessment Test (CAT) score ≥10 and on daily maintenance treatment for their COPD for at least three months prior to study entry.

FULFIL (CTT116853) was a 24-week study (N=1,810), with an extension up to 52 weeks in a subset of subjects (n=430), that compared *TRELEGY ELLIPTA* (92/55/22 micrograms) with budesonide/formoterol 400/12 micrograms (BUD/FOR) administered twice-daily. At screening, the mean post-bronchodilator percent predicted FEV_1 was 45% and 65% of patients reported a history of one or more moderate/severe exacerbation in the past year.

IMPACT (CTT116855) was a 52-week study (N=10,355) that compared *TRELEGY ELLIPTA* (92/55/22 micrograms) with fluticasone furoate/vilanterol 92/22 micrograms (FF/VI) and umeclidinium/vilanterol 55/22 micrograms (UMEC/VI). At screening, the mean post-bronchodilator percent predicted FEV_1 was 46% and over 99% of patients reported a history of one or more moderate/severe exacerbation in the past year.

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

At study entry, the most common COPD medications reported in the FULFIL and IMPACT studies were ICS +LABA+LAMA (28%, 34% respectively), ICS+LABA (29%, 26% respectively), LAMA+LABA (10%, 8% respectively) and LAMA (9%, 7% respectively). These patients may have also been taking other COPD medications (e.g. mucolytics or leukotriene receptor antagonists).

Study 200812 was a 24-week, non-inferiority study (N=1,055) that compared *TRELEGY ELLIPTA* (92/55/22 micrograms) with FF/VI (92/22 micrograms) + UMEC (55 micrograms), co-administered once daily as a multi-inhaler therapy in patients with a history of moderate or severe exacerbations within the prior 12 months.

Lung Function

In FULFIL, bronchodilatory effects with *TRELEGY ELLIPTA* were evident on the first day of treatment and were maintained over the 24-week treatment period (mean changes from baseline in FEV_1 were 90-222 mL on day 1 and 160-339 mL at week 24). *TRELEGY ELLIPTA* significantly improved ($p<0.001$) lung function (as defined by mean change from baseline in trough FEV_1 at week 24) (*see **Table 1***) and the improvement was maintained in the subset of patients who continued treatment to week 52.

Table 1. Lung function endpoint in FULFIL

	***TRELEGY ELLIPTA* (N=911)**	**BUD/FOR (N=899)**	**Treatment difference (95% CI)**
			Comparison with BUD/FOR
Trough FEV_1 (L) at Week 24, LS mean change from baseline (SE)[a]	0.142 (0.0083)	-0.029 (0.0085)	0.171 0.148, 0.194

FEV_1=forced expiratory volume in 1 second; L=litres; LS=least squares; SE=standard error, N=number in the intent-to-treat population; CI=confidence interval, [a] Statistically significant treatment difference for FF/UMEC/VI vs. BUD/FOR also observed at the other assessment timepoints (weeks 2, 4 and 12).

In IMPACT, *TRELEGY ELLIPTA* significantly improved ($p<0.001$) lung function when compared with FF/VI and UMEC/VI over a 52-week period (*see **Table 2***).

Table 2. Lung function endpoint in IMPACT

	***TRELEGY ELLIPTA* (N=4,151)**	**FF/VI (N=4,134)**	**UMEC/VI (N=2,070)**	**Treatment difference 95% CI**	
				Comparison *TRELEGY* vs. FF/VI	**Comparison *TRELEGY* vs. UMEC/VI**
Trough FEV_1 (L) at Week 52, LS mean change from baseline (SE) [a]	0.094 (0.004)	-0.003 (0.004)	0.040 (0.006)	0.097 0.085, 0.109	0.054 0.039, 0.069

FEV_1=forced expiratory volume in 1 second; L=litres; LS=least squares; SE=standard error; N=number in the intent-to-treat population; CI=confidence interval; [a] Statistically significant treatment differences for FF/UMEC/VI vs. FF/VI and FF/UMEC/VI vs. UMEC/VI were also observed at the other assessment timepoints (Weeks 4, 16, 28, and 40).

In Study 200812, *TRELEGY ELLIPTA* was non-inferior compared with FF/VI+UMEC, co-administered in two inhalers, in the improvement from baseline in trough FEV_1 at Week 24. The pre-specified non-inferiority margin was 50 mL.

Exacerbations

In IMPACT, over 52 weeks, *TRELEGY ELLIPTA* significantly reduced ($p<0.001$) the annual rate of moderate/severe exacerbations by 15% (95% CI:10, 20) compared with FF/VI (rate; 0.91 vs 1.07 events per patient year) and by 25% (95% CI: 19, 30) compared with UMEC/VI (rate; 0.91 vs 1.21 events per patient year). In FULFIL, based upon data up to 24 weeks, *TRELEGY ELLIPTA*

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

significantly reduced (p=0.002) the annual rate of moderate/severe exacerbations by 35% (95% CI: 14, 51) compared with BUD/FOR.

In IMPACT, *TRELEGY ELLIPTA* prolonged the time to first moderate/severe exacerbation and significantly decreased (p<0.001) the risk of a moderate/severe exacerbation, as measured by time to first exacerbation, compared with both FF/VI (14.8%; 95% CI: 9.3, 19.9) and UMEC/VI (16.0%; 95% CI: 9.4, 22.1). In FULFIL, *TRELEGY ELLIPTA* significantly decreased the risk of a moderate/severe exacerbation compared with BUD/FOR over 24 weeks (33%; 95% CI: 12, 48; p=0.004).

In IMPACT, treatment with *TRELEGY ELLIPTA* reduced the annual rate of severe exacerbations (i.e., requiring hospitalisation or resulting in death) by 13% compared with FF/VI (95% CI: -1, 24; p=0.064). Treatment with *TRELEGY ELLIPTA* significantly reduced the annual rate of severe exacerbations by 34% compared with UMEC/VI (95% CI: 22, 44; p<0.001).

Health-Related Quality of Life
TRELEGY ELLIPTA significantly improved (p<0.001) Health Related Quality of Life (as measured by the St George's Respiratory Questionnaire [SGRQ] total score) in both FULFIL (Week 24) when compared with BUD/FOR (-2.2 units; 95% CI: -3.5, -1.0) and IMPACT (Week 52) when compared with FF/VI (-1.8 units; 95% CI: -2.4, -1.1) and UMEC/VI (-1.8 units; 95% CI: -2.6, -1.0).

A higher percentage of patients receiving *TRELEGY ELLIPTA* responded with a clinically meaningful improvement in SGRQ total score in FULFIL at Week 24 compared with BUD/FOR (50% and 41% respectively), odds ratios of response vs. non-response (OR) (1.41; 95% CI: 1.16, 1.70) and in IMPACT at Week 52 compared with FF/VI and UMEC/VI (42%, 34% and 34% respectively), OR vs. FF/VI (1.41; 95% CI:1.29, 1.55) and OR vs. UMEC/VI (1.41; 95% CI: 1.26, 1.57); all treatment comparisons were statistically significant (p<0.001).

In FULFIL, the proportion of patients who were CAT responders (defined as 2 units below baseline or lower) at Week 24, was significantly higher (p<0.001) for patients treated with *TRELEGY ELLIPTA* compared with BUD/FOR (53% vs. 45%; OR 1.44; 95% CI: 1.19, 1.75). In IMPACT, the proportion of patients who were CAT responders at Week 52 was significantly higher (p<0.001) for patients treated with *TRELEGY ELLIPTA* (42%) compared with FF/VI (37%; OR 1.24; 95% CI: 1.14, 1.36) and UMEC/VI (36%; OR 1.28; 95% CI: 1.15, 1.43).

Symptom Relief
Breathlessness was measured using the Transition Dyspnoea Index (TDI) focal score at Week 24 in FULFIL and Week 52 in IMPACT (a subset of patients, n=5,058). In FULFIL the proportion of responders according to TDI (defined as at least 1 unit) was significantly higher (p<0.001) for *TRELEGY ELLIPTA* compared with BUD/FOR (61% vs 51%; OR 1.61; 95% CI: 1.33, 1.95). In IMPACT, the proportion of responders was also significantly higher (p<0.001) for *TRELEGY ELLIPTA* (36%) compared with FF/VI (29%; OR 1.36; 95% CI: 1.19, 1.55) and UMEC/VI (30%; OR 1.33; 95% CI: 1.13, 1.57).

In FULFIL, *TRELEGY ELLIPTA* improved daily symptoms of COPD as assessed by E-RS: COPD total score, compared with BUD/FOR (≥2 unit decrease from baseline). The proportion of responders during Weeks 21-24 was significantly higher (p<0.001) for patients treated with *TRELEGY ELLIPTA* compared with BUD/FOR (47% and 37% respectively; OR 1.59; 95% CI: 1.30, 1.94).

Use of Rescue Medication
In FULFIL, *TRELEGY ELLIPTA* significantly reduced (p<0.001) the use of rescue medication between Weeks 1-24 compared with BUD/FOR (treatment difference: -0.2 occasions per day; 95% CI: -0.3, -0.1).

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

In IMPACT, *TRELEGY ELLIPTA* significantly reduced (p<0.001) the use of rescue medication (occasions per day) at each 4-week time period compared with FF/VI and UMEC/VI. At Weeks 49-52, the treatment difference was -0.28 (95% CI: -0.37, -0.19) when compared with FF/VI and -0.30 (95% CI: -0.41, -0.19) with UMEC/VI.

Nighttime awakenings
In IMPACT, *TRELEGY ELLIPTA* statistically significantly reduced the mean number of nighttime awakenings due to COPD compared with FF/VI (-0.05; 95% CI: -0.08, -0.01; p=0.005) and with UMEC/VI (-0.10; 95% CI: -0.14, -0.05; p<0.001) at Weeks 49 to 52. Significant reductions were observed over all other timepoints for UMEC/VI (p<0.001) and for the all but two of the of timepoints for FF/VI (p≤0.021).

4.2 Pharmacokinetic properties
When fluticasone furoate, umeclidinium and vilanterol were administered in combination by the inhaled route from a single inhaler in healthy subjects, the pharmacokinetics of each component were similar to those observed when each active substance was administered either as fluticasone furoate/vilanterol combination or as an umeclidinium/vilanterol combination or umeclidinium monotherapy.

Population pharmacokinetic (PK) analyses were conducted to assess the systemic exposure of fluticasone furoate, umeclidinium, and vilanterol in subjects with asthma. In these analyses, systemic drug levels (steady-state C_{max} and AUC_{0-24}) of fluticasone furoate and vilanterol following fluticasone furoate/umeclidinium/vilanterol (100/62.5/25 micrograms and 200/62.5/25 micrograms) in one inhaler (triple combination) were within the range of those observed following administration of the dual combination of FF/VI with the respective 100 micrograms and 200 micrograms FF doses; the systemic exposure of umeclidinium 62.5 micrograms following fluticasone furoate/umeclidinium/vilanterol in one inhaler was within the range of those observed following administration of umeclidinium 62.5 micrograms as monotherapy.

Population PK analyses for FF/UMEC/VI were conducted using a combined PK dataset from three phase III studies in 821 COPD subjects. Systemic drug levels (steady state C_{max} and AUC) of FF, UMEC and VI following FF/UMEC/VI in one inhaler (triple combination) were within the range of those observed following FF/VI + UMEC as two inhalers, dual combinations (FF/VI and UMEC/VI), as well as individual 14 single inhalers (FF, UMEC and VI). Covariate analysis showed higher FF apparent clearance (42%) when comparing FF/VI to FF/UMEC/VI; however, this is not considered clinically relevant.

Absorption
Fluticasone furoate
Following inhaled administration of fluticasone furoate/umeclidinium/vilanterol in healthy subjects, fluticasone furoate C_{max} occurred at 15 minutes. The absolute bioavailability of fluticasone furoate when administrated as fluticasone furoate/vilanterol by inhalation was 15.2%, primarily due to absorption of the inhaled portion of the dose delivered to the lung, with negligible contribution from oral absorption. Following repeat dosing of inhaled fluticasone furoate /vilanterol, steady state was achieved within 6 days with up to 1.6-fold accumulation

Umeclidinium
Following inhaled administration of fluticasone furoate/umeclidinium/vilanterol in healthy subjects, umeclidinium C_{max} occurred at 5 minutes. The absolute bioavailability of inhaled umeclidinium was on average 13%, with negligible contribution from oral absorption. Following repeat dosing of inhaled umeclidinium, steady state was achieved within 7 to 10 days with 1.5 to 2-fold accumulation.

Vilanterol
Following inhaled administration of fluticasone furoate/umeclidinium/vilanterol in healthy subjects, vilanterol C_{max} occurred at 7 minutes. The absolute bioavailability of inhaled vilanterol was 27%,

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

with negligible contribution from oral absorption. Following repeat dosing of inhaled umeclidinium/vilanterol, steady state was achieved within 6 days with up to 1.5-fold accumulation.

Distribution

Fluticasone furoate

Following intravenous dosing of fluticasone furoate to healthy volunteers, the mean volume of distribution at steady state of 661 litres. Fluticasone furoate has a low association with red blood cells. *In vitro* plasma protein binding in human plasma of fluticasone furoate was high, on average >99.6%.

Umeclidinium

Following intravenous administration of umeclidinium to healthy volunteers, the mean volume of distribution was 86 litres. *In vitro* plasma protein binding in human plasma was on average 89%.

Vilanterol

Following intravenous administration of vilanterol to healthy volunteers, the mean volume of distribution at steady state was 165 litres. Vilanterol has a low association with red blood cells. *In vitro* plasma protein binding in human plasma was on average 94%.

Biotransformation

Fluticasone furoate

In vitro studies showed that fluticasone furoate is primarily metabolised by cytochrome P450 3A4 (CYP3A4) and is a substrate for the P-gp transporter. The primary metabolic route for fluticasone furoate is hydrolysis of the S-fluoromethyl carbothioate group to metabolites with significantly reduced corticosteroid activity. Systemic exposure to the metabolites is low.

Umeclidinium

In vitro studies showed that umeclidinium is primarily metabolised by cytochrome P450 2D6 (CYP2D6) and is a substrate for the P-gp transporter. The primary metabolic routes for umeclidinium are oxidative (hydroxylation, O-dealkylation) followed by conjugation (glucuronidation, etc), resulting in a range of metabolites with either reduced pharmacological activity or for which the pharmacological activity has not been established. Systemic exposure to the metabolites is low.

Vilanterol

In vitro studies showed that vilanterol is primarily metabolised by cytochrome P450 3A4 (CYP3A4) and is a substrate for the P-gp transporter. The primary metabolic routes for vilanterol are O-dealkylation to a range of metabolites with significantly reduced $beta_1$- and $beta_2$-adrenergic agonist activity. Plasma metabolic profiles following oral administration of vilanterol in a human radiolabel study were consistent with high first-pass metabolism. Systemic exposure to the metabolites is low.

Elimination

Fluticasone furoate

The apparent plasma elimination half-life of fluticasone furoate following inhaled administration of fluticasone furoate/vilanterol was, on average, 24 hours. Following intravenous administration, the elimination phase half-life averaged 15.1 hours. Plasma clearance following intravenous administration was 65.4 litres/hour. Urinary excretion accounted for approximately 2% of the intravenously administered dose. Following oral administration, fluticasone furoate was eliminated in humans mainly by metabolism with metabolites being excreted almost exclusively in faeces, with <1% of the recovered radioactive dose eliminated in the urine.

Umeclidinium

Umeclidinium plasma elimination half-life following inhaled dosing for 10 days averaged 19 hours, with 3% to 4% active substance excreted unchanged in urine at steady-state. Plasma clearance following intravenous administration was 151 litres/hour. Following intravenous administration,

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

approximately 58% of the administered radiolabelled dose was excreted in faeces and approximately 22% of the administered radiolabelled dose was excreted in urine. The excretion of the drug-related material in the faeces following intravenous dosing indicated secretion into the bile. Following oral administration, 92% of the administered radiolabelled dose was excreted primarily in faeces. Less than 1% of the orally administered dose (1% of recovered radioactivity) was excreted in urine, suggesting negligible absorption following oral administration.

Vilanterol
Vilanterol plasma elimination half-life following inhaled dosing for 10 days averaged 11 hours. Plasma clearance of vilanterol following intravenous administration was 108 litres/hour. Following oral administration of radiolabelled vilanterol, 70% of the radiolabel was excreted in urine and 30% in faeces. Primary elimination of vilanterol was by metabolism followed by excretion of metabolites in urine and faeces.

Special patient populations
In the asthma population pharmacokinetic analyses (1,265 subjects for fluticasone furoate; 1,263 subjects for vilanterol; 634 subjects for umeclidinium), the impact of demographic covariates (race/ethnicity, age, gender, weight) on the pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol was evaluated. In a COPD population pharmacokinetic analysis (n=821), the impact of demographic covariates (race/ethnicity, age, gender, weight) on the pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol was evaluated. Renal and hepatic impairment were assessed in separate studies.

Race
No clinically relevant differences requiring dose adjustment in asthma or COPD based on race were observed in fluticasone furoate, umeclidinium or vilanterol systemic exposure.

In East Asian subjects with asthma (Japanese, East Asian and Southeast Asian heritage) (n=92) who provided fluticasone furoate/umeclidinium/vilanterol (100/62.5/25 micrograms and 200/62.5/25 micrograms) population pharmacokinetic data, estimates of vilanterol C_{max} at steady state was approximately 3-fold higher than non-East Asian subjects. There was no effect of race on pharmacokinetics of fluticasone furoate or umeclidinium in subjects with asthma.

Elderly
The effects of age on the pharmacokinetics of fluticasone furoate, umeclidinium and vilanterol were evaluated in the population pharmacokinetic analysis. No clinically relevant effects requiring dose adjustment were observed.

Renal impairment
The effect of fluticasone furoate/umeclidinium/vilanterol has not been evaluated in subjects with renal impairment. However, studies have been conducted with fluticasone furoate/vilanterol and umeclidinium/vilanterol that showed no evidence of an increase in systemic exposure to fluticasone furoate, umeclidinium or vilanterol. *In vitro* protein binding studies between subjects with severe renal impairment and healthy volunteers were conducted, and no clinically significant evidence of altered protein binding was seen.

The effects of haemodialysis have not been studied.

Hepatic impairment
The effect of fluticasone furoate/umeclidinium/vilanterol has not been evaluated in subjects with hepatic impairment. However, studies have been conducted with fluticasone furoate/vilanterol and umeclidinium/vilanterol.

The fluticasone furoate/vilanterol component of *TRELEGY ELLIPTA* was assessed in patients with all severities of hepatic impairment (Child-Pugh A, B or C). For fluticasone furoate, patients with moderate hepatic impairment showed up to three times higher systemic exposure (FF 184

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

micrograms); therefore, patients with severe hepatic impairment received half the dose (FF 92 micrograms). At this dose, no effects on systemic exposure were observed. Therefore, caution is advised in moderate to severe hepatic impairment, but no specific dose adjustment based on hepatic function is recommended. There was no significant increase in systemic exposure to vilanterol.

Patients with moderate hepatic impairment showed no evidence of an increase in systemic exposure to either umeclidinium or vilanterol (C_{max} and AUC). Umeclidinium has not been evaluated in patients with severe hepatic impairment.

Other special populations
The effects of race, gender and weight on the pharmacokinetics of fluticasone furoate, umeclidinium and vilanterol were also evaluated in the population pharmacokinetic analysis.

In 113 East Asian subjects with COPD (Japanese and East Asian Heritage), who received FF/UMEC/VI from a single inhaler (27% subjects), fluticasone furoate $AUC_{(ss)}$ estimates were on average 30% higher compared with Caucasian subjects. However, these higher systemic exposures remain below the threshold for FF-induced reduction of serum and urine cortisol and are not considered clinically relevant. There was no effect of race on pharmacokinetic parameters of umeclidinium or vilanterol in subjects with COPD.

No clinically relevant differences requiring dose adjustment based on race, gender or weight were observed in fluticasone furoate, umeclidinium or vilanterol systemic exposure.

In terms of other patient characteristics, a study in CYP2D6 poor metabolisers showed no evidence of a clinically significant effect of CYP2D6 genetic polymorphism on systemic exposure to umeclidinium.

Clinical studies
Asthma
The safety and efficacy of *TRELEGY ELLIPTA* (FF/UMEC/VI) were evaluated in 2,436 subjects in a randomised, multi-centre, active-controlled, double-blind clinical trial of 24 to 52 weeks' duration in adult subjects with asthma inadequately controlled on their current treatments of combination therapy (ICS plus a LABA) (study 205715, CAPTAIN). The trial evaluated the efficacy of *TRELEGY ELLIPTA* on lung function, annualized rate of moderate and severe asthma exacerbations, asthma symptom control, and health-related quality of life when compared with fluticasone furoate/vilanterol. The primary endpoint was change from baseline in trough Forced Expiratory Volume in 1 second (FEV1) at Week 24. The key secondary endpoint was the annualized rate of moderate/severe asthma exacerbation.

This trial had a 5-week run-in/stabilization period described as follows: subjects inadequately controlled [Asthma Control Questionnaire (ACQ-6) ≥1.5] on their current asthma treatment of inhaled corticosteroid (greater than or equivalent to fluticasone propionate 250 micrograms per day) plus LABA entered a 3-week run-in period of treatment with fluticasone proprionate/salmeterol 250/50 micrograms twice daily.

Subjects who remained inadequately controlled (ACQ-6 ≥1.5) after the run-in period were transferred to fluticasone furoate/vilanterol (FF/VI) 100/25 micrograms once daily for a 2-week stabilization period. Across all treatment groups, baseline demographics were similar.

At screening, the mean prebronchodilator percent predicted FEV1 was 58.5% (SD: 12.8%); the mean percent reversibility was 29.9% (SD: 18.1%), with a mean absolute reversibility of 0.484 L (SD: 0.274 L), and the mean ACQ-6 score was 2.5 (SD: 0.6). During the 5-week run in/stabilization period, subjects had substantial improvements in both lung function (trough FEV1 improvement of 0.287 L) and asthma control (mean ACQ-6 score decreased by 0.6). Despite these improvements, a majority of subjects (93%) were not well controlled (mean score ACQ-6 of 1.9), demonstrating

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

the need for additional therapy. At randomization, the mean prebronchodilator percent predicted FEV1 was 68.2% (SD: 14.8%).

After the 5-week run-in/stabilization period, eligible subjects were randomised to receive once-daily inhalations of *TRELEGY ELLIPTA* 100/62.5/25 micrograms (n=406), *TRELEGY ELLIPTA* 200/62.5/25 micrograms (n=408), FF/UMEC/VI 100/31.25/25 micrograms (n=405), FF/UMEC/VI 200/31.25/25 micrograms (n=404), FF/VI 100/25 micrograms (n=407), or FF/VI 200/25 micrograms (n=406).

While 4 doses of *TRELEGY ELLIPTA* were studied in the trial, efficacy data results shown are for *TRELEGY ELLIPTA* 100/62.5/25 micrograms and *TRELEGY ELLIPTA* 200/62.5/25 micrograms, the recommended doses for the treatment of asthma. In the evaluation of efficacy, the non-lung function endpoint analyses included prespecified pooled comparisons of *TRELEGY ELLIPTA* (100/62.5/25 and 200/62.5/25 micrograms) with FF/VI (100/25 and 200/25 micrograms).

The change from baseline in trough FEV1 at Week 24 (primary efficacy endpoint) showed statistically significant improvements in lung function for both *TRELEGY ELLIPTA* 100/62.5/25 micrograms and *TRELEGY ELLIPTA* 200/62.5/25 micrograms compared with FF/VI 100/25 micrograms and FF/VI 200/25 micrograms, respectively (*see* ***Table 3, Figures 1 and 2***).

Table 3. Lung function endpoints (Study 205715)

	FF/VI 100/25 (n=407)	***TRELEGY ELLIPTA* FF/UMEC/VI 100/62.5/25 (n=406)**	**FF/VI 200/25 (n=406)**	***TRELEGY ELLIPTA* FF/UMEC/VI 200/62.5/25 (n=408)**
Trough FEV1 (L) at Week 24				
LS mean change from baseline (SE)	0.024 (0.0157)	0.134 (0.0155)	0.076 (0.0156)	0.168 (0.0155)
FF/UMEC/VI 100/62.5/25 vs. FF/VI 100/25 Treatment difference 95% CI p-value	Reference	0.110 0.066, 0.153 p<0.001	--	--
FF/UMEC/VI 200/62.5/25 vs. FF/VI 200/25 Treatment difference 95% CI p-value	--	--	Reference	0.092 0.049, 0.135 p<0.001
FF/UMEC/VI 200/62.5/25 vs. 100/62.5/25[a] Treatment difference 95% CI	--	Reference	--	0.034 -0.009, 0.077
FF/UMEC/VI 100/62.5/25 vs. FF/VI 200/25[a] Treatment difference 95% CI	--	0.059 0.015, 0.102	Reference	--
FF/UMEC/VI 200/62.5/25 vs. FF/VI 100/25[a] Treatment difference 95% CI	Reference	--	--	0.143 0.100, 0.187
FEV_1 at 3 hours post-dose[b] (L) at Week 24				
LS mean change from baseline (SE)	0.132 (0.0160)	0.243 (0.0158)	0.168 (0.0159)	0.286 (0.0158)

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

FF/UMEC/VI 100/62.5/25 vs. FF/VI 100/25 Treatment difference 95% CI	Reference	0.111 0.067, 0.155	--	--
FF/UMEC/VI 200/62.5/25 vs. FF/VI 200/25 Treatment difference 95% CI	--	--	Reference	0.118 0.074, 0.162
FF/UMEC/VI 200/62.5/25 vs. 100/62.5/25 Treatment difference 95% CI	--	Reference	--	0.044 0, 0.087
FF/UMEC/VI 100/62.5/25 vs. FF/VI 200/25 Treatment difference 95% CI	--	0.075 0.031, 0.119	Reference	--
FF/UMEC/VI 200/62.5/25 vs. FF/VI 100/25 Treatment difference 95% CI	Reference	--	--	0.155 0.110, 0.199

CI=confidence interval; FEV1=forced expiratory volume in 1 second; L=litres; LS=least squared; n=number in the intent-to-treat population; SE=standard error

[a] These comparisons were not in the predefined testing hierarchy and were not adjusted for multiplicity.

[b] Endpoint was not in the predefined testing hierarchy, therefore not adjusted for multiplicity.

Figure 1. Least Squares (LS) Mean Change from Baseline in Trough FEV1 (L) for *TRELEGY ELLIPTA* 100/62.5/25 micrograms



Figure 2. Least Squares (LS) Mean Change from Baseline in Trough FEV1 (L) for *TRELEGY ELLIPTA* 200/62.5/25 micrograms

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076



Moderate/severe asthma exacerbations were assessed over the 52-week treatment period (*see **Table 4***). In the pooled analysis, the annualized rate of moderate/severe exacerbations was numerically lower with *TRELEGY ELLIPTA* (100/62.5/25 and 200/62.5/25 micrograms) compared with FF/VI (100/25 and 200/25 micrograms) (13% reduction in rate; 95% CI: -5.2, 28.1). Descriptive analyses of unpooled treatment comparisons for the annualized rate of moderate/severe exacerbations are also provided.

Table 4. Annualised Rate of Moderate/Severe Exacerbationsa (Up to 52 Weeks) (Study 205715)

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

	FF/VI 100/25 (n=407)	***TRELEGY ELLIPTA* FF/UMEC/VI 100/62.5/25 (n=406)**	**FF/VI 200/25 (n=406)**	***TRELEGY ELLIPTA* FF/UMEC/VI 200/62.5/25 (n=408)**
Mean Annualised Rate	0.87	0.68	0.57	0.55
FF/UMEC/VI 100/62.5/25 vs. FF/VI 100/25 Reduction in Rate (%) 95% CI	Reference	21.8% -1.1, 39.5	---	---
FF/UMEC/VI 200/62.5/25 vs. FF/VI 200/25 Reduction in Rate (%) 95% CI	---	---	Reference	3.2% -28.2, 27.0
FF/UMEC/VI 200/62.5/25 vs. 100/62.5/25 Reduction in Rate (%) 95% CI	---	Reference	---	19.1% -6.4, 38.5
FF/UMEC/VI 100/62.5/25 vs. FF/VI 200/25 Change in Rate (%) 95% CI	---	-19.6%[b] -57.2, 9.0	Reference	---
FF/UMEC/VI 200/62.5/25 vs. FF/VI 100/25 Reduction in Rate (%) 95% CI	Reference	---	---	36.7% 17.6, 51.5

CI=confidence interval; n=number in the intent-to-treat population.
[a] These comparisons were not in the predefined testing hierarchy and were not adjusted for multiplicity.
[b] Negative percentage reflects an increase in exacerbation rate for FF/UMEC/VI 100/62.5/25 vs. FF/VI 200/25.

In addition, severe asthma exacerbations were assessed. In a descriptive pooled analysis, a difference in the mean annualised rate of severe exacerbations was not observed for *TRELEGY ELLIPTA* (100/62.5/25 and 200/62.5/25 micrograms) compared with FF/VI (100/25 and 200/25 micrograms) (2.6% reduction in rate; 95% CI: -26.2, 24.9). The mean annualised rates of severe exacerbations were 0.41 and 0.23 for *TRELEGY ELLIPTA* 100/62.5/25 micrograms and *TRELEGY ELLIPTA* 200/62.5/25 micrograms, respectively. The mean annualised rates of severe exacerbations were 0.38 and 0.26 for FF/VI 100/25 micrograms and FF/VI 200/25 micrograms, respectively.

Patient symptoms and health-related quality of life were assessed using the ACQ, the Evaluating Respiratory Symptoms in Asthma (E-RS: Asthma), and the St. George's Respiratory Questionnaire (SGRQ) (*see* ***Table 5***). In a descriptive pooled analysis, the ACQ-7 responder rate was 63% for *TRELEGY ELLIPTA* (100/62.5/25 and 200/62.5/25 micrograms) compared with 55% for FF/VI (100/25 and 200/25 micrograms) at Week 24 (OR: 1.43; 95% CI: 1.16, 1.76). Descriptive analyses of unpooled treatment comparisons are also provided.

Table 5. Asthma Control Questionnaire (ACQ)-7 Resultsa at Week 24 (Study 205715)

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

	FF/VI 100/25 (n=407)	*TRELEGY ELLIPTA* FF/UMEC/VI 100/62.5/25 (n=406)	FF/VI 200/25 (n=406)	*TRELEGY ELLIPTA* FF/UMEC/VI 200/62.5/25 (n=408)
Responder[b] (%)	52%	62%	58%	64%
FF/UMEC/VI 100/62.5/25 vs. FF/VI 100/25 Odds Ratio 95% CI	Reference	1.59 1.18, 2.13	---	---
FF/UMEC/VI 200/62.5/25 vs. FF/VI 200/25 Odds Ratio 95% CI	---	---	Reference	1.28 0.95, 1.72
FF/UMEC/VI 200/62.5/25 vs. 100/62.5/25 Odds Ratio 95% CI	---	Reference	---	1.08 0.80, 1.45
FF/UMEC/VI 100/62.5/25 vs. FF/VI 200/25 Odds Ratio 95% CI	---	1.19 0.88, 1,60	Reference	---
FF/UMEC/VI 200/62.5/25 vs. FF/VI 100/25 Odds Ratio 95% CI	Reference	---	---	1.71 1.27, 2.30

CI=confidence interval; n=number in the intent-to-treat population
[a] These comparisons were not in the predefined testing hierarchy and were not adjusted for multiplicity.
[b] Defined as an ACQ-7 score ≥0.5 below baseline.

The ACQ-5 (comprising the 5 questions on symptoms from ACQ-7) responder rates at Week 24 were similar to the ACQ-7 results. In a pooled descriptive analysis, the ACQ-5 responder rate was 64% for *TRELEGY ELLIPTA* (100/62.5/25 and 200/62.5/25 micrograms) compared with 60% for FF/VI (100/25 and 200/25 micrograms) (OR: 1.23; 95% CI: 1.00, 1.52) at Week 24.

In an unpooled descriptive analysis, the ACQ-5 responder rate was 63% for *TRELEGY ELLIPTA* 100/62.5/25 micrograms compared with 58% for FF/VI 100/25 micrograms (OR: 1.28; 95% CI: 0.96, 1.72) at Week 24. The ACQ-5 responder rate was 66% for *TRELEGY ELLIPTA* 200/62.5/25 micrograms compared with 62% for FF/VI 200/25 micrograms (OR: 1.19; 95% CI: 0.88, 1.60) at Week 24.

In a pooled descriptive analysis, the E-RS: Asthma responder rate (defined as a decrease in score of ≥2 from baseline) was 45% with *TRELEGY ELLIPTA* (100/62.5/25 and 200/62.5/25 micrograms) compared with 41% for FF/VI (100/25 and 200/25 micrograms) (OR: 1.18; 95% CI: 0.96, 1.45) (Weeks 21-24).

In an unpooled descriptive analysis, the E-RS: Asthma responder rate was 42% for *TRELEGY ELLIPTA* 100/62.5/25 micrograms compared with 38% for FF/VI 100/25 micrograms (OR: 1.22; 95% CI: 0.91, 1.63) (Weeks 21-24). The E-RS: Asthma responder rate was 47% for *TRELEGY ELLIPTA* 200/62.5/25 micrograms compared with 44% for FF/VI 200/25 micrograms (OR: 1.15; 95% CI: 0.86, 1.53) (Weeks 21-24).

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

In a pooled descriptive analysis, the SGRQ responder rate (defined as a decrease in score of ≥4 from baseline) was 69% for *TRELEGY ELLIPTA* (100/62.5/25 and 200/62.5/25 micrograms) compared with 66% for FF/VI (100/25 and 200/25 micrograms) (OR: 1.14; 95% CI: 0.92, 1.42) at Week 24.

In an unpooled descriptive analysis, the SGRQ responder rate was 68% for *TRELEGY ELLIPTA* 100/62.5/25 micrograms compared with 64% for FF/VI 100/25 micrograms (OR: 1.26; 95% CI: 0.93, 1.70) at Week 24. The SGRQ responder rate was 69% for *TRELEGY ELLIPTA* 200/62.5/25 micrograms compared with 68% for FF/VI 200/25 micrograms (OR: 1.04; 95% CI: 0.76, 1.41) at Week 24.

4.3 Pre-clinical safety data

Pharmacological and toxicological effects seen with fluticasone furoate, umeclidinium or vilanterol in non-clinical studies were those typically associated with glucocorticoids, muscarinic receptor antagonists, or beta$_2$-adrenergic receptor agonists. Administration of combined fluticasone furoate, umeclidinium and vilanterol to dogs did not result in any significant new toxicity or any major exacerbation of expected findings associated with fluticasone furoate, umeclidinium or vilanterol alone.

Genotoxicity and carcinogenicity

Fluticasone furoate

Fluticasone furoate was not genotoxic in a standard battery of studies and was not carcinogenic in lifetime inhalation studies in rats or mice at exposures of 1.4- or 2.9-fold, respectively, those seen in humans at a daily dose of 92 micrograms fluticasone furoate, based on AUC.

Umeclidinium

Umeclidinium was not genotoxic in a standard battery of studies and was not carcinogenic in lifetime inhalation studies in mice or rats at exposures ≥20- or ≥17-fold the human clinical exposure at a daily dose of 55 micrograms umeclidinium, based on AUC respectively.

Vilanterol

Vilanterol (as alpha-phenylcinnamate) and triphenylacetic acid were not genotoxic indicating that vilanterol (as trifenatate) does not represent a genotoxic hazard to humans. Consistent with findings for other beta$_2$ agonists, in lifetime inhalation studies vilanterol trifenatate caused proliferative effects in the female rat and mouse reproductive tract and rat pituitary gland. There was no increase in tumour incidence in rats or mice at exposures 0.9- or 22-fold, respectively, the human clinical exposure of vilanterol at a daily dose of 22 micrograms based on AUC.

Toxicity to reproduction

Fluticasone furoate, umeclidinium and vilanterol did not have any adverse effects on male or female fertility in rats.

Fluticasone furoate

Fluticasone furoate was not teratogenic in rats or rabbits, but delayed development in rats and caused abortion in rabbits at maternally toxic doses. There were no effects on development in rats at exposures 6.6-fold the human clinical exposure at a daily dose of 92 micrograms, based on AUC. Fluticasone furoate had no adverse effect on pre-or post-natal development in rats.

Umeclidinium

Umeclidinium was not teratogenic in rats or rabbits. In a pre- and post-natal study, subcutaneous administration of umeclidinium to rats resulted in lower maternal body weight gain and food consumption and slightly decreased pre-weaning pup body weights in dams given 180 micrograms/kg/day dose (approximately 61-fold the human clinical exposure of umeclidinium at a daily dose of 55 micrograms, based on AUC).

Vilanterol

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

Vilanterol was not teratogenic in rats. In inhalation studies in rabbits, vilanterol caused effects similar to those seen with other beta$_2$-adrenergic agonists (cleft palate, open eyelids, sternebral fusion and limb flexure/malrotation). When given subcutaneously there were no effects at exposures 62-fold the human clinical exposure at a daily dose of 22 micrograms, based on AUC. Vilanterol had no adverse effect on pre- or post-natal development in rats.

5. PHARMACEUTICAL PARTICULARS

5.1 List of excipients

Lactose monohydrate
Magnesium stearate

5.2 Incompatibilities

Not applicable.

5.3 Shelf life

The expiry date is indicated on the packaging.

Shelf life after opening the tray: 1 month.

5.4 Special precautions for storage

Do not store above 30°C.

If stored in a refrigerator allow the inhaler to return to room temperature for at least an hour before use.

Keep the inhaler inside the sealed tray in order to protect from moisture and only remove immediately before first use.

Write the date that the inhaler should be discarded on the label and carton in the space provided. The date should be added as soon as the inhaler has been removed from the tray.

5.5 Nature and contents of container

The *ELLIPTA* inhaler consists of a light grey body, beige mouthpiece cover and a dose counter, packed into a foil laminate tray containing a silica gel desiccant sachet. The tray is sealed with a peelable foil lid.

The inhaler is a multi-component device composed of polypropylene, high density polyethylene, polyoxymethylene, polybutylene terephthalate, acrylonitrile butadiene styrene, polycarbonate and stainless steel.

The inhaler contains two aluminium foil laminate blister strips that deliver a total of 30 doses (30 days supply). Each blister in one strip contains fluticasone furoate, each blister in the other strip contains umeclidinium (as bromide) and vilanterol (as trifenatate).

Pack sizes of 30 dose inhalers.

5.6 Special precautions for disposal

After inhalation, patients should rinse their mouth with water without swallowing.

The *ELLIPTA* inhaler contains pre-dispensed doses and is ready to use.

The inhaler is packaged in a tray containing a desiccant sachet, to reduce moisture. The desiccant sachet should be thrown away and it should not be opened, eaten or inhaled. The patient should be advised to not open the tray until they are ready to inhale a dose.

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

The inhaler will be in the ‘closed’ position when it is first taken out of its sealed tray. The “Discard by” date should be written on the inhaler label and carton in the space provided. The date should be added as soon as the inhaler has been removed from the tray. The “Discard by” date is 1 month from the date of opening the tray. After this date the inhaler should no longer be used. The tray can be discarded after first opening.

If the inhaler cover is opened and closed without inhaling the medicinal product, the dose will be lost. The lost dose will be securely held inside the inhaler, but it will no longer be available to be inhaled.

It is not possible to accidentally take extra medicine or a double dose in one inhalation.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

PACKAGE QUANTITIES AND REGISTRATION NUMBER

TRELEGY ELLIPTA 100/62.5/25 mcg	Reg. No. DKI2275705167A1
TRELEGY ELLIPTA 200/62.5/25 mcg	Reg. No. XXXXXXXXXXXXXXX

Box, 1 inhaler *ELLIPTA* @ 30 doses

HARUS DENGAN RESEP DOKTER

Manufactured by
Glaxo Operations UK Limited
Ware, United Kingdom

Imported by
PT Glaxo Wellcome Indonesia
Jakarta, Indonesia

Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor.

Version number : 01
Reference : EU PI version EMEA/H/C/IG1340 (16 Feb 2021) + asthma indication
Data of local revision : 16 Feb 2024

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

INFORMASI UNTUK PASIEN

TRELEGY ELLIPTA
Fluticasone furoate/ Umeclidinium bromide/ Vilanterol trifenatate

Obat ini memerlukan pengawasan tambahan untuk mempercepat identifikasi informasi keamanan baru. Anda dapat membantu dengan melaporkan efek samping apapun yang mungkin Anda alami. Lihat *Bagian 4* untuk mengetahui bagaimana caranya melaporkan efek samping.

Baca keseluruhan brosur ini secara teliti sebelum Anda mulai menggunakan *TRELEGY ELLIPTA* karena brosur ini mengandung informasi penting untuk Anda.
- Simpan petunjuk ini. Anda mungkin membutuhkannya untuk dibaca kembali.
- Jika Anda memiliki pertanyaan lebih lanjut, tanyakan kepada dokter, apoteker, atau perawat.
- *TRELEGY ELLIPTA* ini hanya diresepkan kepada Anda. Jangan diberikan kepada orang lain. Hal tersebut dapat membahayakan mereka, meskipun gejala penyakit mereka sama dengan gejala Anda.
- Jika Anda merasakan efek samping, bicarakan dengan dokter, apoteker, atau perawat. Termasuk kemungkinan efek samping lain yang tidak tertulis dalam petunjuk ini. Lihat *Bagian 4*.

Apa saja yang ada dalam petunjuk ini:

1 Apa itu *TRELEGY ELLIPTA* dan apa kegunaannya

Apa itu *TRELEGY ELLIPTA*
TRELEGY ELLIPTA mengandung tiga zat aktif yaitu fluticasone furoate, umeclidinium bromide dan vilanterol. Fluticasone furoate masuk ke dalam golongan obat kortikosteroid, biasa disebut steroid. Umeclidinium bromide dan vilanterol masuk ke dalam golongan obat bronkodilator. *TRELEGY ELLIPTA* terdiri dari dua jenis kekuatan yang berbeda: fluticasone furoate 100 mikrogram/umeclidinium 62,5 mikrogram/vilanterol 25 mikrogram dan fluticasone furoate 200 mikrogram/umeclidinium 62,5 mikrogram/vilanterol 25 mikrogram.

Apa kegunaan *TRELEGY ELLIPTA*
TRELEGY ELLIPTA digunakan untuk terapi pemeliharaan **asma** dan terapi pemeliharaan Penyakit Paru Obstruktif Kronis (**PPOK**) pada pasien dewasa. Asma adalah gangguan ketika otot di sekitar saluran pernapasan menyempit (bronkokonstriksi), sembab, dan terjadi peradangan (inflamasi). Gejala yang muncul dan hilang termasuk di antaranya adalah sesak napas, mengi, dada terasa sesak, dan batuk. PPOK adalah penyakit paru kronis yang ditandai dengan keluhan kesulitan bernapas yang semakin memburuk.

Pada asma dan PPOK, otot di sekitar saluran penapasan menyempit, membuat pasien kesulitan bernapas. *TRELEGY ELLIPTA* akan memperlebar otot pada paru, mengurangi pembengkakan dan peradangan pada saluran pernapasan kecil dan mempermudah keluar masuknya udara. Ketika digunakan secara teratur, *TRELEGY ELLIPTA* dapat membantu mengontrol kesulitan bernapas dan mengurangi efek dari asma dan PPOK dalam kehidupan sehari-hari.

TRELEGY ELLIPTA 100/62,5/25 digunakan untuk terapi asma dan PPOK pada pasien dewasa.
TRELEGY ELLIPTA 200/62,5/25 digunakan untuk terapi asma pada pasien dewasa. *TRELEGY ELLIPTA* 200/62,5/25 tidak disetujui untuk terapi PPOK.

***TRELEGY ELLIPTA* harus digunakan setiap hari dan bukan hanya saat Anda mengalami gangguan pernapasan atau gejala asma atau PPOK lainnya. *TRELEGY ELLIPTA* tidak**

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

digunakan untuk melegakan serangan mendadak sesak napas atau mengi. Apabila Anda mengalami serangan ini, Anda harus segera menggunakan *inhaler* pelega kerja-pendek (seperti salbutamol). Beritahu dokter jika Anda tidak memiliki *inhaler* pelega kerja-pendek.

2 Apa yang perlu Anda ketahui sebelum menggunakan *TRELEGY ELLIPTA*

Jangan gunakan *TRELEGY ELLIPTA*:
Jika Anda alergi terhadap fluticasone furoate, umeclidinium, vilanterol, atau bahan lain dari *TRELEGY ELLIPTA (terdaftar di Bagian 6).*

Peringatan dan perhatian
Konsultasikan dengan dokter Anda sebelum menggunakan *TRELEGY ELLIPTA*:
- Jika Anda memiliki **gangguan jantung** atau **tekanan darah tinggi**.
- Jika Anda memiliki **gangguan hati**.
- Jika Anda memiliki **Tuberkulosis** (TB) **pada paru**, atau **infeksi yang berlangsung lama** maupun **infeksi yang belum tertangani**.
- Jika Anda memiliki gangguan penglihatan yang disebut **glaukoma sudut sempit**.
- Jika Anda mengalami **pembengkakan prostat**, **kesulitan buang air kecil** atau terjadi **sumbatan pada kandung kemih**.
- Jika Anda menderita **epilepsi**.
- Jika Anda memiliki **gangguan kelenjar tiroid**.
- Jika Anda memiliki kadar **kalium yang rendah** dalam darah.
- Jika Anda memiliki riwayat **diabetes**.
- Jika Anda mengalami penglihatan kabur atau **gangguan penglihatan** lainnya.

Konsultasikan dengan dokter jika Anda merasa kondisi di atas berlaku pada Anda.

Kesulitan bernapas mendadak
Jika Anda merasakan sesak pada dada, batuk, mengi atau sesak napas sesaat setelah menggunakan *TRELEGY ELLIPTA*:

Hentikan penggunaan obat ini dan segera cari pertolongan medis, karena Anda mungkin mengalami gangguan serius yang disebut paradoksikal bronkospasme.

Gangguan penglihatan selama terapi menggunakan *TRELEGY ELLIPTA*
Jika Anda merasakan nyeri atau rasa tidak nyaman pada mata, penglihatan kabur sementara, muncul lingkaran cahaya atau bayangan berwarna dan juga mata merah selama terapi menggunakan *TRELEGY ELLIPTA*:

Hentikan penggunaan obat ini dan segera cari pertolongan medis, hal ini mungkin merupakan gejala gangguan akut glaukoma sudut sempit.

Infeksi paru
Karena Anda menggunakan *TRELEGY ELLIPTA* untuk terapi PPOK, Anda memiliki risiko yang lebih tinggi untuk mengalami infeksi paru yang disebut pneumonia. Lihat *Bagian 4* 'Efek samping yang mungkin terjadi' untuk informasi gejala yang perlu diperhatikan ketika menggunakan obat ini.

Segera beritahukan dokter jika Anda merasakan salah satu gejala tersebut.

Anak-anak dan remaja
Jangan berikan obat ini pada anak-anak atau remaja di bawah umur 18 tahun.

Obat lain dan *TRELEGY ELLIPTA*
Beritahukan dokter atau apoteker jika Anda sedang, baru saja, atau akan menggunakan obat lain. Jika Anda tidak yakin terkait komposisi obat yang dikonsumsi, sampaikan pada dokter atau apoteker.

Beberapa obat dapat mempengaruhi cara kerja *TRELEGY ELLIPTA*, atau membuat Anda memiliki risiko lebih tinggi untuk mengalami efek samping. Obat tersebut meliputi:
- Obat yang dikenal sebagai penghambat beta (seperti propranolol), untuk terapi **tekanan darah tinggi** atau **gangguan jantung** lainnya.
- Ketoconazole atau itraconazole, untuk terapi **infeksi yang disebabkan oleh jamur**.
- Clarithromycin atau telithromycin, untuk terapi **infeksi yang disebabkan oleh bakteri**.
- Ritonavir atau cobicistat, untuk terapi **infeksi HIV**.

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

- Obat yang menurunkan jumlah kalium dalam darah, seperti beberapa diuretik atau beberapa obat untuk terapi PPOK dan asma (seperti methylxanthine atau steroid).
- Obat kerja-panjang lain yang mirip dengan *TRELEGY ELLIPTA* yang digunakan untuk terapi gangguan pernapasan, seperti tiotropium, indacaterol. Jangan gunakan *TRELEGY ELLIPTA* jika Anda sudah menggunakan obat-obatan tersebut.

Beritahukan dokter atau apoteker jika Anda sedang menggunakan obat-obatan di atas. Dokter akan mengawasi jika Anda sedang menggunakan obat-obatan tersebut karena dapat meningkatkan efek samping *TRELEGY ELLIPTA*.

Kehamilan dan menyusui
Jika Anda hamil atau menyusui, merasa mungkin hamil, atau berencana untuk memiliki anak, konsultasikan dengan dokter Anda sebelum menggunakan *TRELEGY ELLIPTA*. Jangan menggunakan obat ini ketika Anda sedang hamil, kecuali dokter Anda memperbolehkan.

Tidak diketahui apakah kandungan pada *TRELEGY ELLIPTA* dapat masuk ke dalam ASI. **Jika Anda sedang menyusui, konsultasikan dengan dokter Anda** sebelum menggunakan *TRELEGY ELLIPTA*. Jangan menggunakan obat ini ketika Anda sedang menyusui, kecuali dokter Anda memperbolehkan.

Berkendara dan menjalankan mesin
TRELEGY ELLIPTA cenderung tidak mempengaruhi kemampuan Anda mengemudi atau menjalankan mesin.

***TRELEGY ELLIPTA* mengandung laktosa**
Jika Anda pernah diberitahu oleh dokter bahwa Anda intoleran terhadap gula atau protein susu, konsultasikan dengan dokter Anda sebelum menggunakan *TRELEGY ELLIPTA*.

3 Bagaimana menggunakan *TRELEGY ELLIPTA*

Selalu gunakan obat sesuai petunjuk dokter. Pastikan dengan dokter atau apoteker apabila Anda merasa ragu.

Berapa banyak dosis yang digunakan
Asma
Dosis yang direkomendasikan untuk terapi asma adalah satu hirupan (100 mikrogram fluticasone furoate, 62,5 mikrogram umeclidinium dan 25 mikrogram vilanterol) setiap hari pada waktu yang sama. Berdasarkan derajat keparahan asma, dokter Anda dapat memberikan dosis yang lebih tinggi (200 mikrogram fluticasone furoate, 62,5 mikrogram umeclidinium dan 25 mikrogram vilanterol) satu hirupan setiap hari pada waktu yang sama.

PPOK
Dosis yang direkomendasikan adalah satu hirupan (100 mikrogram fluticasone furoate, 62,5 mikrogram umeclidinium dan 25 mikrogram vilanterol) setiap hari pada waktu yang sama. Dosis yang lebih tinggi (200 mikrogram fluticasone furoate, 62,5 mikrogram umeclidinium dan 25 mikrogram vilanterol) tidak dapat digunakan untuk terapi PPOK.

Anda hanya perlu menggunakan obat satu kali sehari karena obat akan memberikan efek selama 24 jam.

Jangan gunakan obat dengan dosis lebih dari yang dokter Anda perintahkan.

Gunakan *TRELEGY ELLIPTA* secara teratur
Sangat penting untuk menggunakan *TRELEGY ELLIPTA* setiap hari, seperti yang dianjurkan oleh dokter. Hal ini akan membantu Anda terbebas dari munculnya gejala sepanjang hari.

TRELEGY ELLIPTA **tidak** digunakan untuk mengatasi **serangan mendadak dari sesak napas atau mengi**. Jika Anda mengalami hal ini, Anda harus segera menggunakan *inhaler* pelega kerja-pendek (seperti salbutamol).

Bagaimana cara menggunakan *inhaler ELLIPTA*

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

Lihat *Bagian 7* 'Cara pakai' dalam brosur ini untuk informasi lengkapnya.

TRELEGY ELLIPTA digunakan melalui inhalasi.

Saat *tray* telah dibuka maka *TRELEGY ELLIPTA* siap untuk digunakan.

Jika gejala Anda tidak membaik
Jika gejala Anda (sesak napas, mengi, batuk) tidak membaik atau menjadi semakin buruk, atau jika Anda menjadi lebih sering menggunakan *inhaler* kerja-pendek:
hubungi dokter Anda sesegera mungkin.

Jika Anda menggunakan *TRELEGY ELLIPTA* lebih dari yang seharusnya
Jika Anda secara tidak sengaja menggunakan *TRELEGY ELLIPTA* lebih banyak, **segera hubungi dokter atau apoteker untuk mendapatkan petunjuk** dikarenakan Anda mungkin membutuhkan penanganan medis. Apabila memungkinkan, tunjukkan *inhaler ELLIPTA*, kemasan, dan juga brosur ini. Anda mungkin merasakan jantung Anda berdetak lebih cepat dari biasanya, tubuh gemetar, penglihatan terganggu, mulut kering, atau sakit kepala.

Jika Anda lupa untuk menggunakan *TRELEGY ELLIPTA*
Jangan menggunakan dosis ganda untuk mengganti dosis yang terlewatkan. Cukup gunakan dosis selanjutnya di waktu yang sama. Jika Anda merasakan mengi atau sesak napas, gunakan *inhaler* pelega kerja-pendek (seperti salbutamol), kemudian segera cari bantuan medis.

Jangan menghentikan penggunaan *TRELEGY ELLIPTA* tanpa saran dokter
Gunakan *TRELEGY ELLIPTA* sesuai dengan jangka waktu yang direkomendasikan dokter. Jangan menghentikan penggunaan kecuali disarankan oleh dokter, bahkan meski Anda merasa sehat. Penghentian penggunaan obat tanpa saran dokter dapat menyebabkan gejala Anda memburuk.

Jika Anda memiliki pertanyaan lebih lanjut terkait penggunaan obat ini, tanyakan dokter, apoteker, atau perawat.

4 Efek samping yang mungkin terjadi

Seperti obat lainnya, obat ini dapat menyebabkan efek samping, meski tidak semua pasien mengalaminya. Dokter Anda akan mempertimbangkan risiko dari efek samping ketika memberikan dosis *TRELEGY ELLIPTA* yang sebaiknya Anda gunakan.

Reaksi alergi
Reaksi alergi pada penggunaan *TRELEGY ELLIPTA* jarang terjadi (terjadi hingga 1 dalam 1.000 pasien).

Jika Anda merasakan gejala di bawah ini setelah menggunakan *TRELEGY ELLIPTA*, **hentikan penggunaan** dan **segera hubungi dokter**.
- Ruam pada kulit atau kemerahan, gatal-gatal (urtikaria)
- Bengkak, kadang pada wajah atau mulut (angioedema)
- Mengi, batuk, atau kesulitan bernapas
- Mendadak merasa lemah atau kepala terasa ringan (yang dapat mengakibatkan jatuh atau hilang kesadaran)

Kesulitan bernapas mendadak
Jika napas atau mengi Anda memburuk sesaat setelah menggunakan *TRELEGY ELLIPTA*, **hentikan penggunaan** dan **segera cari bantuan medis**.

Pneumonia (infeksi paru) pada pasien PPOK (efek samping yang umum terjadi).
Beritahukan dokter jika Anda mengalami gejala berikut saat menggunakan *TRELEGY ELLIPTA* – kondisi di bawah ini mungkin merupakan gejala dari infeksi paru:
- Demam atau meriang
- Produksi dahak meningkat, perubahan warna dahak
- Batuk meningkat atau meningkatnya kesulitan bernapas

Efek samping umum terjadi

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

Hal ini mungkin dapat terjadi pada **≤1/10** pasien:
- Nyeri pada mulut atau tenggorokan, infeksi jamur pada mulut atau tenggorokan (kandidiasis). Membilas mulut dengan air segera setelah menggunakan *TRELEGY ELLIPTA* dapat mencegah terjadinya efek samping ini.
- Infeksi pada hidung, sinus atau tenggorokan.
- Infeksi pada saluran pernapasan atas.
- Hidung terasa gatal, berair, atau tersumbat.
- Nyeri pada bagian belakang mulut dan tenggorokan.
- Peradangan pada sinus.
- Peradangan pada paru (bronkitis).
- Flu (influenza).
- Flu biasa.
- Sakit kepala.
- Batuk.
- Sering kencing, nyeri saat kencing (kemungkinan tanda infeksi saluran kencing).
- Nyeri sendi.
- Nyeri punggung.
- Konstipasi.

Efek samping tidak umum terjadi
Hal ini mungkin dapat terjadi pada **≤1/100** pasien:
- Denyut jantung yang tidak teratur.
- Denyut jantung yang lebih cepat.
- Suara serak.
- Melemahnya tulang, mengarah ke patah tulang.
- Mulut kering.

Efek samping jarang terjadi
Hal ini mungkin dapat terjadi pada **≤1/1.000** pasien:
- Reaksi alergi (lihat *Bagian 4* 'Efek samping yang mungkin terjadi').

Efek samping lain
Efek samping lain dapat terjadi namun frekuensinya tidak diketahui (frekuensi tidak dapat diperkirakan dari data yang tersedia):
- Pandangan kabur.

Pelaporan efek samping
Jika Anda merasakan efek samping, laporkan ke dokter, apoteker, atau perawat. Termasuk kemungkinan efek samping lain yang tidak tertulis dalam brosur ini. Anda dapat melaporkan kejadian efek samping ini melalui kanal pelaporan milik perusahaan pada alamat email: yqq68540@gsk.com. Dengan melaporkan efek samping, Anda dapat membantu memberikan informasi lebih terhadap keamanan obat ini.

5 Bagaimana cara penyimpanan *TRELEGY ELLIPTA*

Hindarkan obat ini dari pandangan dan jangkauan anak-anak.

Jangan menggunakan obat setelah tanggal kedaluwarsa yang tertera pada karton, *tray*, dan *inhaler* setelah kata 'EXP'. Tanggal kedaluwarsa merujuk pada hari terakhir bulan tersebut.

Jangan simpan di atas suhu 30°C.

Simpan *inhaler* dalam kemasan *tray* yang tersegel untuk melindungi obat dari kelembaban dan buka kemasan hanya pada saat *inhaler* siap untuk digunakan untuk pertama kalinya. Setelah *tray* dibuka, *inhaler ELLIPTA* dapat digunakan hingga 1 bulan ke depan, dimulai dari tanggal pembukaan kemasan *tray*. Tulis tanggal saat *inhaler ELLIPTA* harus dimusnahkan pada bagian label *inhaler* yang tersedia. Tanggal harus ditambahkan segera setelah *inhaler* dibuka dari kemasan *tray*.

Jika disimpan di dalam kulkas, tunggu sampai suhu *inhaler ELLIPTA* kembali ke suhu ruangan minimal satu jam sebelum penggunaan.

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

Jangan membuang obat apapun di limbah rumah tangga. Tanyakan pada apoteker bagaimana membuang obat yang tidak digunakan lagi. Langkah ini membantu dalam menjaga lingkungan.

6 Isi dari kemasan dan informasi lain

Apa kandungan *TRELEGY ELLIPTA*
Zat aktif *TRELEGY ELLIPTA* adalah fluticasone furoate, umeclidinium bromide, dan vilanterol.

TRELEGY ELLIPTA 100/62,5/25: setiap satu hirupan memberikan dosis terhantar (dosis yang meninggalkan *mouthpiece*) sebanyak 92 mikrogram fluticasone furoate, 65 mikrogram umeclidinium bromide setara dengan 55 mikrogram umeclidinium, dan 22 mikrogram vilanterol (dalam bentuk trifenatate).

TRELEGY ELLIPTA 200/62,5/25: setiap satu hirupan memberikan dosis terhantar (dosis yang meninggalkan *mouthpiece*) sebanyak 184 mikrogram fluticasone furoate, 65 mikrogram umeclidinium bromide setara dengan 55 mikrogram umeclidinium, dan 22 mikrogram vilanterol (dalam bentuk trifenatate).

Bahan lainnya adalah lactose monohydrate (lihat *Bagian 2* pada "*TRELEGY ELLIPTA* mengandung laktosa") dan magnesium stearate.

Seperti apa bentuk *TRELEGY ELLIPTA* dan isi dari kemasan
TRELEGY ELLIPTA adalah serbuk inhalasi, *pre-dispensed*.

Inhaler ELLIPTA terdiri dari komponen plastik abu-abu muda, tutup *mouthpiece* berwarna krem, dan penghitung dosis. *TRELEGY ELLIPTA* dikemas dalam *tray* terlaminasi *foil* dengan tutup *foil* yang dapat dikelupas. Di dalam *tray* terdapat penyerap lembab untuk mengurangi kelembaban di dalam kemasan.

Zat aktif berupa serbuk putih pada blister terpisah di dalam *inhaler ELLIPTA*. Tiap *inhaler* mengandung 30 dosis untuk penggunaan 30 hari.

7 Cara pakai

Apa itu *inhaler ELLIPTA*?
Saat pertama kali Anda menggunakan *TRELEGY ELLIPTA*, Anda tidak perlu mencoba apakah *inhaler ELLIPTA* bekerja dengan baik; *inhaler* sebelumnya telah terisi dengan dosis terukur dan siap untuk langsung digunakan.

Kandungan dalam kemasan karton *TRELEGY ELLIPTA*



DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

Inhaler dikemas dalam *tray.* **Jangan membuka *tray* hingga Anda siap untuk menghirup dosis obat**. Saat Anda siap untuk menggunakan *inhaler ELLIPTA*, kupas tutup *tray*. *Tray* berisi sebungkus penyerap lembab untuk mengurangi kelembaban. Buanglah penyerap lembab tersebut, **jangan** dibuka, dimakan, atau dihirup.



Ketika Anda mengambil *inhaler ELLIPTA* keluar dari *tray*, *inhaler ELLIPTA* masih dalam keadaan 'tertutup'. **Jangan membukanya hingga Anda siap untuk menghirup dosis obat**. Tulis 'tanggal pemusnahan' pada bagian label *inhaler* yang tersedia. Tanggal pemusnahan adalah 1 bulan dari tanggal *tray* dibuka. **Setelah 'tanggal pemusnahan' tersebut sebaiknya *inhaler ELLIPTA* tidak digunakan lagi.** *Tray* dapat dimusnahkan setelah dibuka pertama kali.

1) Baca langkah berikut sebelum Anda memulai
Jika Anda membuka dan menutup tutup tanpa menghirup obat, Anda akan kehilangan dosis. Dosis yang hilang akan aman tertahan di dalam *inhaler*, namun tidak lagi dapat digunakan.

Tidak memungkinkan untuk secara tidak sengaja menggunakan kelebihan dosis atau dosis ganda dalam satu hirupan.

Penghitung dosis
Penghitung dosis menunjukkan berapa dosis yang masih tersisa di dalam *inhaler ELLIPTA*.

Sebelum *inhaler ELLIPTA* digunakan, penghitung akan menunjukkan tepat 30 dosis.

Penghitung ini akan berkurang **1** angka setiap Anda membuka tutup.

Saat dosis tersisa kurang dari 10, separuh penghitung dosis akan berwarna merah.

Setelah Anda menggunakan dosis terakhir, **separuh penghitung dosis akan berwarna merah dan angka 0 akan ditunjukkan**. *Inhaler ELLIPTA* kosong.

Jika Anda membuka tutup setelahnya, penghitung dosis akan berubah menjadi merah total.

Tutup
Setiap Anda membuka tutup ini, satu dosis obat telah siap untuk dihirup (dosis berkurang).



DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076

2) Menyiapkan dosis

Buka tutup saat Anda sudah siap menggunakan dosis Anda.
Jangan kocok *inhaler ELLIPTA*.

- Tarik tutup ke bawah hingga terdengar bunyi 'klik'.



Sekarang, obat Anda siap untuk dihirup.
Penghitung dosis berkurang **1** untuk memastikannya.

- **Jika penghitung dosis Anda tidak berkurang ketika terdengar bunyi 'klik', *inhaler* Ellipta tidak akan menghantarkan obat.** Tanyakan hal ini kepada apoteker untuk meminta saran.
- **Jangan pernah kocok *inhaler ELLIPTA*.**

3) Hirup obat Anda

- **Bersamaan dengan Anda memegang *inhaler* jauh dari mulut, hembuskan napas sebanyak dan senyaman Anda.**
  Jangan hembuskan napas ke dalam *inhaler*.
- **Letakkan *mouthpiece* di antara bibir Anda, dan tutup rapat menyelubungi *mouthpiece.***
  Jangan tutup ventilasi udara dengan jari Anda.

- Tarik satu napas kuat dan panjang melalui mulut. Tahan napas tersebut selama Anda mampu (minimal 3-4 detik).
- Lepas *inhaler ELLIPTA* dari mulut Anda.
- Hembuskan napas perlahan.

Kemungkinan Anda tidak dapat merasakan obatnya, meski Anda menggunakan *inhaler* dengan benar.

Jika Anda ingin membersihkan *mouthpiece,* gunakan **tisu kering, sebelum** menutup penutupnya.

4) Penutupan *inhaler ELLIPTA* dan berkumur

- Geser tutup ke atas sejauh dapat tergeser untuk menutup *mouthpiece*.

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076



- **Berkumurlah dengan air untuk membasuh mulut Anda setelah menggunakan *inhaler*, jangan ditelan.**
  Dengan demikian kemungkinan kecil Anda akan mengalami sakit pada mulut atau tenggorokan sebagai efek samping.

HARUS DENGAN RESEP DOKTER

TRELEGY ELLIPTA 100/62.5/25 mikrogram	Reg. No. DKI2275705167A1
TRELEGY ELLIPTA 200/62.5/25 mikrogram	Reg. No. XXXXXXXXXXXXXXX

Dus, 1 *inhaler ELLIPTA* @ 30 dosis

Diproduksi oleh
Glaxo Operations UK Limited
Ware, Inggris

Diimpor oleh
PT Glaxo Wellcome Indonesia
Jakarta, Indonesia

Merek dagang dimiliki oleh atau dilisensikan kepada grup perusahaan GSK.
©2023 grup perusahaan GSK atau pemberi lisensinya.

Version number	: 01
Reference	: Version 3 + redactional
Data of local revision	: 21 Feb 2024

DISETUJUI OLEH BPOM : 20/06/2024 ID : EREG10035212300076